TNOX Tanox (MM)

HOUSTON, Dec. 7 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will have two poster presentations on its HIV viral-entry inhibitor antibody, TNX-355, at the American Society for Microbiology's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Dec. 16-19, 2005 in Washington, D.C. The presentations will be made Dec. 17, from 1:30 to 3 p.m., EST, at the Washington Convention Center (Poster Board BA in Hall B). Phase 2 Week 24 efficacy results will be highlighted, in addition to TNX-355's activity against CCR5 and CXCR4 viruses and results of in vitro combination studies with enfuvirtide. Tanox will host an investor/analyst briefing in Washington following the poster session. The briefing is scheduled from 4 to 5 p.m., EST, and will be accessible by conference call for those unable to attend. To join the conference call, dial 1-866-800-8652 (access code 3879-5703). About TNX-355 TNX-355 is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing the entry of HIV particles into lymphocytes. TNX-355 is the first antibody in development for the treatment of HIV and AIDS. A Phase 2 clinical study demonstrated that TNX-355, plus optimized background therapy, produces a clinical meaningful reduction in viral load against multiple strains of HIV, without depleting CD4-positive cells. TNX-355 was fast tracked by the Food and Drug Administration in 2003. The fast-track designation expedites approval of therapies for life-threatening diseases and allows for rolling new drug application (NDA) submissions. About Tanox, Inc. Tanox is a biotechnology company specializing in the discovery and development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiretroviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is currently approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com/. http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE: Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, or Web site: http://www.tanox.com/

Copyright